Murat Gunay1, Mehmet Ali Sekeroglu2, Handan Bardak3, Gokhan Celik1, Cenap Mahmut Esenulku4, Emre Hekimoglu5, Yavuz Bardak3. 1. a Zeynep Kamil Maternity and Children's Diseases Training and Research Hospital , Department of Ophthalmology , Istanbul , Turkey. 2. b Ulucanlar Training and Research Hospital , Department of Ophthalmology , Ankara , Turkey. 3. c Haydarpasa Training and Research Hospital , Department of Ophthalmology , Istanbul , Turkey. 4. d Trabzon Kanuni Training and Research Hospital , Department of Ophthalmology , Trabzon , Turkey. 5. e Etlik Zubeyde Hanim Maternity and Children's Diseases Training and Research Hospital , Department of Ophthalmology , Ankara , Turkey.
Abstract
PURPOSE: To assess ocular biometric outcomes following intravitreal bevacizumab (IVB) monotherapy for retinopathy of prematurity (ROP) and compare these results with those of laser photocoagulated infants and with the ones with spontaneously regressed ROP. MATERIALS AND METHODS: Premature infants including those who underwent IVB monotherapy (Group 1) or laser photocoagulation (Group 2) for ROP and infants with spontaneously regressed ROP (Group 3) were recruited for the study. Refractive errors and ocular biometric parameters (Axial length [AL], anterior chamber depth [ACD], and lens thickness [LT]) were measured at adjusted 1 year of age in all subjects. RESULTS: There was no significant difference of spherical equivalent (SE) value between the groups (P = 0.781). The incidence of high myopia was 7.4% in Group 1 and 12.7% in Group 2 (P = 0.081). No infants exhibited high myopia in Group 3. LT was greater in Group 2 when compared to Group 1 and Group 3 (P = 0.011). Lower SE was significantly correlated to longer AL in Group 1 (r = -0.656, P = 0.015). There was a significant positive correlation between SE and ACD values in Group 2 (r = 0.391, P = 0.005). CONCLUSION: The study showed no significant difference of SE between the groups. High myopia was only present among the treated infants either with IVB or laser. Infants who received laser treatment significantly had thicker lenses.
PURPOSE: To assess ocular biometric outcomes following intravitreal bevacizumab (IVB) monotherapy for retinopathy of prematurity (ROP) and compare these results with those of laser photocoagulated infants and with the ones with spontaneously regressed ROP. MATERIALS AND METHODS: Premature infants including those who underwent IVB monotherapy (Group 1) or laser photocoagulation (Group 2) for ROP and infants with spontaneously regressed ROP (Group 3) were recruited for the study. Refractive errors and ocular biometric parameters (Axial length [AL], anterior chamber depth [ACD], and lens thickness [LT]) were measured at adjusted 1 year of age in all subjects. RESULTS: There was no significant difference of spherical equivalent (SE) value between the groups (P = 0.781). The incidence of high myopia was 7.4% in Group 1 and 12.7% in Group 2 (P = 0.081). No infants exhibited high myopia in Group 3. LT was greater in Group 2 when compared to Group 1 and Group 3 (P = 0.011). Lower SE was significantly correlated to longer AL in Group 1 (r = -0.656, P = 0.015). There was a significant positive correlation between SE and ACD values in Group 2 (r = 0.391, P = 0.005). CONCLUSION: The study showed no significant difference of SE between the groups. High myopia was only present among the treated infants either with IVB or laser. Infants who received laser treatment significantly had thicker lenses.
Entities:
Keywords:
Biometry; intravitreal injection; refraction; retinopathy of prematurity
Authors: Michael Simmons; Jingyun Wang; Joel N Leffler; Shanshan Li; Sarah E Morale; Angie de la Cruz; Eileen E Birch Journal: Transl Vis Sci Technol Date: 2021-04-01 Impact factor: 3.283